PRESS RELEASE published on 08/25/2025 at 08:00, 10 months 2 days ago Informations privilégiées / Autres communiqués TME Pharma lève 500 000 € via une émission obligataire pour accélérer ses activités de développement de thérapies innovantes. Nouveau soutien financier renforce la position de TME Pharma Développement Financement Émission Obligataire TME Pharma Thérapies Innovantes
BRIEF published on 07/08/2025 at 08:05, 11 months 19 days ago TME Pharma met fin à son contrat de liquidité dans le cadre d'une optimisation des coûts Contrat De Liquidité Biotechnologie Optimisation Des Coûts Refinancement TME Pharma
BRIEF published on 07/08/2025 at 08:05, 11 months 19 days ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 11 months 19 days ago Informations privilégiées / Autres communiqués TME Pharma annonce la résiliation du contrat de liquidité avec Invest Securities pour optimiser ses coûts et renforcer sa trésorerie. Réduction des coûts opérationnels suite à la restructuration organisationnelle Contrat De Liquidité Optimisation Des Coûts TME Pharma Restructuration Organisationnelle Développement Thérapies
PRESS RELEASE published on 07/08/2025 at 08:00, 11 months 19 days ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
BRIEF published on 05/21/2025 at 08:05, 1 year 1 month ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
BRIEF published on 05/21/2025 at 08:05, 1 year 1 month ago TME Pharma améliore ses perspectives financières avec un engagement obligataire de 1,7 million d'euros Partenariats Stratégiques Emission D'obligations Programmes Cliniques Visibilité Financière Structure Des Coûts
PRESS RELEASE published on 05/21/2025 at 08:00, 1 year 1 month ago Informations privilégiées / Autres communiqués TME Pharma, société de biotechnologie spécialisée en thérapies contre le cancer, prolonge sa visibilité financière jusqu'en mai 2026 via une émission d'obligations aux investisseurs professionnels Investisseurs Obligations Cancer Visibilité Financière TME Pharma
PRESS RELEASE published on 05/21/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
BRIEF published on 04/10/2025 at 19:05, 1 year 2 months ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
Published on 06/27/2026 at 16:50, 8 hours 19 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 23 hours 29 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 1 hour ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 2 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 2 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 1 hour ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 1 hour ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 1 hour ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 1 hour ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 1 hour ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
